Market Size of miRNA Sequencing and Assay Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
CAGR | 10.90 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
MiRNA Sequencing and Assay Market Analysis
The miRNA sequencing and assay market is expected to register a CAGR of 10.9% during the forecast period.
- The COVID-19 pandemic significantly impacted healthcare systems worldwide, leading to disruptions in usual care and exposing vulnerable cancer patients to increased risks. While vaccines have been approved to combat SARS-CoV-2 infection, miRNAs have emerged as a potential alternative. These miRNAs can detect SARS-CoV-2 infection by binding to its genome and limiting its post-transcriptional expression, thereby reducing the severity of COVID-19 disease.
- Notably, miR-21-3p has demonstrated the strongest binding affinity to the human coronavirus genome. With the rising number of COVID-19 cases, there is increasing demand for effective treatments, including next-generation sequencing technologies and miRNA sequencing.
- In addition to their potential in COVID-19 pathogenesis, miRNAs are critical in assessing the development, progression, prognosis, diagnosis, and treatment response in cancer patients. Some miRNAs function as tumor suppressors, while others act as oncogenes. For example, miR-451 has been identified as a potential prognostic factor in head and neck squamous cell carcinomas (HNSCCs) through miRNA profiling. The clusters of miR-375 and miR-106b-25 are implicated in the development and progression of HNSCCs. Furthermore, miRNAs have shown promise in forensic medicine due to their stability and specificity, making them useful for degraded samples or complex mixes.
- Investments in genomics have increased in recent years, with companies such as Ultima Genomics and Deep Genomics receiving significant funding for their sequencing and AI discovery platforms. Despite this growth, the market for miRNA sequencing may be hindered by a lack of expertise and computing infrastructure.
- Overall, the market for miRNA sequencing is expected to witness strong growth due to the increasing demand for effective COVID-19 treatments and the critical role of miRNAs in cancer diagnosis and treatment. However, addressing the challenges related to expertise and computing infrastructure will be crucial for sustaining this growth.
MiRNA Sequencing and Assay Industry Segmentation
miRNA sequencing is a type of RNA-seq that uses next-generation sequencing or massively parallel sequencing of high-throughput DNA to pattern microRNAs. The substance used during the method of decoding miRNA; this sequencing is a bit different from RNA sequencing.
The miRNA sequencing and assay market is segmented by product (sequencing consumables and library preparation kits), technology (sequencing by synthesis, ion semiconductor, solid, nanopore sequencing), end user (clinical laboratory, life science organization, others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value (in USD million) for the above segments.
By Product | |
Sequencing Consumables | |
Library Preparation Kits |
By Technology | |
Sequencing by Synthesis | |
Ion Semiconductor | |
SOLiD | |
Nanopore Sequencing |
By End-User | |
Clinical Laboratory | |
Life Science Organization | |
Other End-Users |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
miRNA Sequencing and Assay Market Size Summary
The miRNA sequencing and assay market is poised for robust expansion, driven by the increasing application of miRNAs in various fields such as cancer diagnosis, treatment, and COVID-19 research. The market is experiencing a surge in demand due to the critical role of miRNAs in understanding cancer progression and their potential in developing effective COVID-19 treatments. The adoption of next-generation sequencing technologies is further propelling market growth, as these technologies offer advanced capabilities in miRNA profiling and analysis. Despite the promising growth trajectory, the market faces challenges related to the need for specialized expertise and adequate computing infrastructure, which are essential for leveraging the full potential of miRNA sequencing technologies.
In North America, the miRNA sequencing and assay market is expected to witness significant growth, fueled by the high incidence of cancer and the increasing demand for precision medicine. The presence of major industry players and substantial investments in research and development are key factors contributing to regional growth. Companies like Illumina, Inc., Thermo Fisher Scientific, and Qiagen N.V. are leading the market with their innovative products and technologies. The market is moderately competitive, with major players actively engaging in strategic collaborations and product launches to enhance their market positions. The development of advanced tools and technologies, such as Qiagen's QIAseq miRNA Library Kit, is expected to drive further growth in the market, addressing the rising need for effective miRNA sequencing solutions.
miRNA Sequencing and Assay Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 MiRNA Sequencing and Assay Sequencing Supremacy Over Other Methods
-
1.2.2 Increased Research in the Field of Genomics
-
1.2.3 Reduced Sequencing Costs
-
-
1.3 Market Restraints
-
1.3.1 Paucity of Expert and Need for Computing Infrastructure
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size - Value in USD million)
-
2.1 By Product
-
2.1.1 Sequencing Consumables
-
2.1.2 Library Preparation Kits
-
-
2.2 By Technology
-
2.2.1 Sequencing by Synthesis
-
2.2.2 Ion Semiconductor
-
2.2.3 SOLiD
-
2.2.4 Nanopore Sequencing
-
-
2.3 By End-User
-
2.3.1 Clinical Laboratory
-
2.3.2 Life Science Organization
-
2.3.3 Other End-Users
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle-East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle-East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
miRNA Sequencing and Assay Market Size FAQs
What is the current miRNA Sequencing and Assay Market size?
The miRNA Sequencing and Assay Market is projected to register a CAGR of 10.90% during the forecast period (2024-2029)
Who are the key players in miRNA Sequencing and Assay Market?
Illumina, Inc., Thermo Fisher Scientific, Qiagen N.V., Perkinelmer, Inc. and Takara Bio, Inc. are the major companies operating in the miRNA Sequencing and Assay Market.